Who to call at Genmab A/S, and when
Fundz watches for the moments Genmab A/S starts buying, and tells you who to reach.
- An alert the day Genmab A/S raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Genmab A/S, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Genmab A/S. With Fundz connected, it knows.
Genmab and Incyte collaborate on a colorectal cancer trial using petosemtamab and a mutation-targeting drug.
Contract Type
partnership
CopenhagenBiotechnologyHealth CareTherapeuticsDescription
Genmab A/S and Incyte Corporation announced a collaboration for a first-line colorectal cancer study. The Phase 1/2 trial will pair petosemtamab with a mutation-targeting drug and chemotherapy, focusing on patients with the KRAS G12D mutation.
Quick answer
Genmab and Incyte collaborate on a colorectal cancer trial using petosemtamab and a mutation-targeting drug. (October 24, 2026). Genmab A/S is based in Copenhagen, Capital Region Of Denmark, Denmark.
- What agreement did Genmab A/S announce on October 24, 2026?
- Genmab A/S and Incyte Corporation announced a collaboration for a first-line colorectal cancer study. The Phase 1/2 trial will pair petosemtamab with a mutation-targeting drug and chemotherapy, focusing on patients with the KRAS G12D mutation.
- What does Genmab A/S do?
- Genmab A/S is a publicly traded biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.
- Where is Genmab A/S based?
- Genmab A/S is based in Copenhagen, Capital Region Of Denmark, Denmark.
- Which similar companies announced agreements around the same time?
- Georgiamune (October 25, 2026), GondolaBio (October 26, 2026), Cognito Therapeutics (October 27, 2026) and Prothena Corporation (October 20, 2026) also announced agreements within 45 days of Genmab A/S.
Source: Fundz verified event record.
Other recent agreements in Therapeutics and Biotechnology
Contracts and agreements at companies in the same sectors within 45 days, from Fundz verified event records.
- Menarini and Georgiamune Enter $1.1 Billion License Agreement for Cancer Immunotherapy GIM-621. (October 25, 2026)
- GondolaBio and Children’s Tumor Foundation Partner to Enhance Neurofibromatosis Type 1 Program Development. (October 26, 2026)
- Rhode Island Life Science Hub and Cognito Therapeutics launch partnership for Alzheimer's research. (October 27, 2026)
- Prothena Partners with Roche to Advance Prasinezumab for Parkinson's Disease Treatment. (October 20, 2026)
- DARPA Awards Up to $10.7 Million Contract to RxMP Therapeutics for Development of RMP-402. (October 20, 2026)
- YD Bio and EG BioMed Form Partnership with JoiiUp to Launch AI Cancer Risk Assessment for Corporate Wellness. (October 20, 2026)
Related People
Agreement Insights
What this usually meansGenmab A/S signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.